Table 2.
Eosinophilic inflammation in subjects in the Asklepios Study.
| Controls | Current Asthma | Ever Asthma | Sub-Clinical COPD | Clinical COPD | ACO | |
|---|---|---|---|---|---|---|
| Eosinophil count (cells/µL) | 130.0 (80.0–200.0) | 160.0 (110.0–250.0) * | 170.0 (110.0–230.0) | 140.0 (90.0–210.0) ** | 160.0 (110.0–220.0) * | 180.0 (80.0–340.0) |
| Eosinophil count ULN/≥ 310 (%) | 159 (9.0%) | 23 (17.2%) * | 5 (22.7%) * | 11 (10.8%) | 15 (14.7%) | 3 (27.3%) |
| Eosinophil percentage (%) | 2.0 (1.3–3.0) | 2.4 (1.6–3.8) * | 2.3 (1.8–5.4) | 2.2 (1.4–3.3) | 2.3 (1.6–3.5) * | 2.4 (1.3–5.0) |
| Eosinophil percentage ULN/≥4.6, (%) | 165 (9.3%) | 22 (16.4%) * | 6 (27.3%) * | 9 (8.8%) | 19 (18.6%) * | 3 (27.3%) * |
Comparison of median blood eosinophil count in cases versus controls; ACO = Asthma and COPD overlap; ULN = upper limit of normal (90th percentile). * p < 0.05. ** p < 0.1.